About Us
An Innovative Biotech with a Robust R&D Engine for the Development of First-in-Class and Best-In-Class Ophthalmic Drugs
Cloudbreak Pharma is a clinical-stage ophthalmic drug company with a proprietary technology, Multi-Kinase Inhibitors (MKI), that is de-risked with human clinical results and is uniquely suitable for both front-of-eye and back-of-eye diseases.
Under the MKI platform, Cloudbreak’s lead asset, the eye drop CBT-001, is in mid-Phase 3 in multiple regions for the treatment of pterygium, a disease impacting 15 million people in the US alone. Its second asset, CBT-004, is entering Phase 3 for pinguecula, a disease impacting about half of all people over age 70. CBT-001 and CBT-004 will potentially be the first and only FDA-approved drug therapies for these high-value conditions. The Company has additional technologies with pre-clinical through Phase 2 product candidates.
The Cloudbreak team is comprised of experienced ophthalmologic scientists and business professionals who are uniquely qualified to bring product candidates from pre-clinical to NDA approval.
Management
Jinsong Ni, Ph.D
Founder, Chief Executive Officer
Van Dinh, MBA
Chief Operating Officer
Rong Yang, Ph.D
Chief Scientific Officer
Abu Abraham, MD
Chief Medical Officer
Michael Rowe, M.Sc
Chief Business Officer
Greg Brooks, B.Sc
Chief Commercial Officer
Scientific Advisory Board
Our Partners
Santen Pharmaceutical Co., Ltd.
(TYO:4536)
In August 2024, Cloudbreak and Santen entered into a licensing agreement for CBT-001, Cloudbreak’s investigational proprietary multi-kinase inhibitor for the treatment of pterygium in, to develop, manufacture and commercialize the drug products in Japan, South Korea, Vietnam, Thailand, Malaysia, Philippines, Singapore, and Indonesia.
Grand Pharma
(00512.HK)
In April 2020, Cloudbreak and Grand Pharma entered into a commercialisation licensing arrangement which Grand Pharma is granted with an exclusive, sublicensable,
royalty-bearing license to manufacture
and commercialise CBT-001 in mainland
China, Hong Kong, Macau and Taiwan
region.